Protalix BioTherapeutics (PLX) Revenue (2010 - 2026)
Protalix BioTherapeutics (PLX) posted quarterly Revenue of $33.8 million for Q1 2026, up 233.73% year-over-year from $10.1 million in Q1 2025, and up 269.98% quarter-over-quarter from $9.1 million in Q4 2025.
Protalix BioTherapeutics (PLX) Revenue (2010 - 2026) Analysis & Trends
Protalix BioTherapeutics' Revenue history runs 17 years deep, the most recent figure standing at $33.8 million for Q1 2026.
- In Q1 2026, Revenue rose 233.73% year-over-year to $33.8 million; the TTM figure through Mar 2026 stood at $76.4 million (up 27.8% YoY), while the FY2025 annual figure was $52.7 million, down 1.23% from the prior year.
- Revenue for Q1 2026 stood at $33.8 million, up from $9.1 million in the prior quarter.
- The five-year high for Revenue was $35.1 million in Q2 2023, with the low at $3.7 million in Q1 2024.
- The 5-year median for Revenue is $13.5 million (2024), against an average of $14.9 million.
- The sharpest annual moves came in 2023 and 2024: Revenue jumped 300.72% in 2023, then tumbled 61.59% in 2024.
- Protalix BioTherapeutics' Revenue stood at $8.6 million in 2022, then rose by 21.69% to $10.5 million in 2023, then soared by 73.74% to $18.2 million in 2024, then plunged by 49.93% to $9.1 million in 2025, then surged by 269.98% to $33.8 million in 2026.
- Business Quant data shows PLX's Revenue at $33.8 million in Q1 2026, $9.1 million in Q4 2025, and $17.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 145.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.71 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.29 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 425.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 674.14 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 1.06 Bn |
| 10 | Protalix BioTherapeutics | 190.37 Mn | 149.71 Mn | 12.13 Mn | 19.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 19.90 Mn |
| Mar 31, 2026 | 33.75 Mn |
| Dec 31, 2025 | 9.12 Mn |
| Sep 30, 2025 | 17.85 Mn |
| Jun 30, 2025 | 15.66 Mn |
| Mar 31, 2025 | 10.11 Mn |
| Dec 31, 2024 | 18.22 Mn |
| Sep 30, 2024 | 17.96 Mn |
| Jun 30, 2024 | 13.47 Mn |
| Mar 31, 2024 | 3.75 Mn |
| Dec 31, 2023 | 10.49 Mn |
| Sep 30, 2023 | 10.35 Mn |
| Jun 30, 2023 | 35.08 Mn |
| Mar 31, 2023 | 9.59 Mn |
| Dec 31, 2022 | 8.62 Mn |
| Sep 30, 2022 | 14.18 Mn |
| Jun 30, 2022 | 8.75 Mn |
| Mar 31, 2022 | 16.09 Mn |
| Dec 31, 2021 | 8.55 Mn |
| Sep 30, 2021 | 12.05 Mn |